drugset / Trial / NCT07425522
A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety, tolerability, Pharmacodynamics (PD), and Pharmacokinetics (PK) of multiple doses of RO7823653 in participants with DME, administered by intravitreal (IVT) injection as monotherapy and co-administered with faricimab.
Timeline
- Start
- 2026-04-21
- Primary completion
- 2028-11-17
- Completion
- 2028-11-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Faricimab | Monoclonal antibody | — | Intravitreal |
| Subject | RO7823653 | Unknown | — | Intravitreal |